{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-001109","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2025-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.192249+00:00","generated_at":"2026-05-28T11:23:23.073513+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AEON Biopharma prices $20M public offering of units and warrants to fund operations through 2025","bullets":["Gross proceeds ~$20M from 40M units at $0.50/unit; each unit includes one share or Pre-Funded Warrant plus two Series A and B Warrants at $0.625 exercise.","Series A Warrants exercisable after stockholder approval, expire 60 months; Series B Warrants exercisable after approval, expire 30 months with cashless option.","Aegis Capital Corp. sole book-runner; underwriter has 45-day option to purchase up to 15% additional shares/warrants for over-allotments.","Expected close Jan 7, 2025; net proceeds for general corporate purposes and development of ABP-450 botulinum toxin biosimilar.","CEO Marc Forth: capital sufficient through 2025; plans BPD Type 2 meeting with FDA in 2025 to discuss next steps."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-001109","json":"https://secwatch.observer/filing/0001104659-25-001109.json","markdown":"https://secwatch.observer/filing/0001104659-25-001109.md","text":"https://secwatch.observer/filing/0001104659-25-001109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000110465925001109/0001104659-25-001109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000110465925001109/tm2432042d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T11:23:23.073513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}